Evaluation of the LIAISON ANA screen assay for antinuclear antibody testing in autoimmune diseases.
Antinuclear antibodies (ANA) are widely detected by immunofluorescence on HEp-2 cells in patients with connective tissue diseases and other pathological conditions. We evaluated the first-automated chemiluminescence immunoassay for the detection of ANA (LIAISON ANA screen, DiaSorin). This study was carried out simultaneously in two laboratories by testing 327 patient samples with clinically defined connective diseases, 273 routine samples for ANA screening, and 300 blood donors. A total of 268 out of 337 IIF-positive sera were positive with LIAISON ANA screen (79.5% of agreement) and 240 out of 263 IIF-negative sera were negative with LIAISON ANA screen (91.2% of agreement). After resolution of discrepant results, the concordance reached, respectively, 94.9% and 98.8%. The specificity was 99.3% and the sensitivity was 94%. Unlike results obtained by other ANA screening assays, we observed acceptable sensitivity and specificity. Despite the presence of HEp-2 cell extract, we failed to detect some antibodies as antinucleolar, antinuclear envelope, and antiproliferating cell nuclear antigen. This automated assay allows quick process to results and exhibits satisfactory sensitivity for the detection of the main ANA specificities of connective tissue diseases.
Ghillani
P
P
Laboratoire d'Immunochimie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France. pascale.ghillani-dalbin@psl.aphp.fr
Rouquette
A M
AM
Desgruelles
C
C
Hauguel
N
N
Le Pendeven
C
C
Piette
J C
JC
Musset
L
L
D000328:Adult; D000974:Antibodies, Antinuclear / Q000097:blood* / Q000276:immunology; D001327:Autoimmune Diseases / Q000097:blood* / Q000175:diagnosis* / Q000276:immunology; D001782:Blood Donors; D005260:Female; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods*; D008875:Middle Aged